<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(1)</volume><submitter>Lee EY</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Unverified drug allergy labels are common and associated with significant patient harm, yet infrastructure and testing practices vary across clinical settings in Canada.&lt;h4>Objective&lt;/h4>To characterize variability in drug allergy management among allergists in Canada and identify setting-specific barriers to drug allergy testing and desensitization.&lt;h4>Methods&lt;/h4>We developed a peer-reviewed 40-item survey, distributed via the Canadian Society of Allergy and Clinical Immunology, to assess practice patterns, testing modalities, and perceived barriers among allergists. Descriptive statistics and Fisher's exact test were used to evaluate responses by practice setting.&lt;h4>Results&lt;/h4>Sixty-six allergists responded (30% estimated response rate), with 48.4% solely practicing</pubmed_abstract><journal>Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology</journal><pagination>41</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12462252</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characterizing drug allergy management among allergists in Canada: a national survey study.</pubmed_title><pmcid>PMC12462252</pmcid><pubmed_authors>Lee B</pubmed_authors><pubmed_authors>Ruiz J</pubmed_authors><pubmed_authors>Lee EY</pubmed_authors><pubmed_authors>Song C</pubmed_authors><pubmed_authors>Jeimy S</pubmed_authors><pubmed_authors>Krishnan S</pubmed_authors><pubmed_authors>Picard M</pubmed_authors><pubmed_authors>Rosenfield L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characterizing drug allergy management among allergists in Canada: a national survey study.</name><description>&lt;h4>Background&lt;/h4>Unverified drug allergy labels are common and associated with significant patient harm, yet infrastructure and testing practices vary across clinical settings in Canada.&lt;h4>Objective&lt;/h4>To characterize variability in drug allergy management among allergists in Canada and identify setting-specific barriers to drug allergy testing and desensitization.&lt;h4>Methods&lt;/h4>We developed a peer-reviewed 40-item survey, distributed via the Canadian Society of Allergy and Clinical Immunology, to assess practice patterns, testing modalities, and perceived barriers among allergists. Descriptive statistics and Fisher's exact test were used to evaluate responses by practice setting.&lt;h4>Results&lt;/h4>Sixty-six allergists responded (30% estimated response rate), with 48.4% solely practicing</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-04T07:53:48.156Z</modification><creation>2026-05-07T03:08:37.676Z</creation></dates><accession>S-EPMC12462252</accession><cross_references><pubmed>40993713</pubmed><doi>10.1186/s13223-025-00981-4</doi></cross_references></HashMap>